期刊文献+

金刚烷胺对帕金森病患者角膜内皮细胞损害作用的研究 被引量:10

Adverse reaction of amantadine on corneal endothelial cells in patients with Parkinson's disease
暂未订购
导出
摘要 目的评估金刚烷胺对帕金森病(PD)患者角膜内皮细胞的损害作用。方法对120例口服金刚烷胺的PD患者(金刚烷胺治疗组)、30例未服用金刚烷胺的PD患者及50例非PD对照者进行横断面调查。通过裂隙灯显微镜检,比较各组内皮细胞密度、六角形细胞出现率和细胞变异系数的差异。本研究同时就累积剂量和治疗持续时间对金刚烷胺治疗组6个亚组的上述指标,与对照组进行比较。结果非PD对照组、未服用金刚烷胺的PD组及金刚烷胺治疗组患者角膜内皮细胞的平均密度分别为(2825.3±52.4)/mm2、(2820.8±46.9)/mm2和(2659.5±32.1)/mm2;六角形细胞出现率分别为(59.2±1.2)%、(61.9±0.9)%和(57.1±1.2)%;变异系数分别为(34.0±1.3)、(33.1±1.0)和(37.5±0.7),金刚烷胺治疗组各指标与未服用金刚烷胺的PD组和非PD对照组患者相比,差异均有统计学意义的显著性(P<0.05)。金刚烷胺治疗组各亚组比较结果提示,角膜内皮细胞平均密度和六角形细胞出现率随金刚烷胺服用剂量的增加和服用时间的延长呈下降趋势。结论口服金刚烷胺可造成患者角膜内皮细胞损伤,其作用可能有时间和剂量依赖性。 Objective To assess the adverse reaction of amantadine on corneal endothelial cells in patients with Parkinson's disease (PD). Methods A cross-sectional study was performed among 120 PD patients who were administered with amantadine (amantadine-treated group), 30 PD patients who were not administered with amantadine (non- amantadine-treated group), and 50 non-PD patients (non-PD control group). Endothelial cell density, occurrence rate of hexagonal cells, and coefficient of variation were measured by slit-lamp biomicroscopy and were compared among 3 groups. The amantadine-treated group was further divided into six sub-groups according to the cumulative dose and duration of treatment. Results Mean endothelial cell density of non-PD control group, non-amantadine-treated group and amantadine-treated group were (2825.3 + 52.4)/mm2, (2820.8 + 46.9)/mm2 and (2659.5 + 32.1)/mm2 respectively. Occurrence rate of hexagonal cells in non-PD control group, non-amantadine-treated group and amantadine-treated group were (59.2±1.2) %, (61.9±0.9) % and (57.1 ± 1.2) % respectively. Coefficient of variation in non-PD control group, non- amantadine-treated group and amantadine-treated group were (34.0± 1.3), (33.1± 1.0) and (37.5 ±0.7) respectively. There were significant differences between amantadine-treated group and non-PD control group or amantadine-treated group and non-amantadine-treated group (P〈0.05). Longer duration and higher cumulative dose of amantadine therapy led to a greater reduction in endothelial cell density and occurrence rate of hexagonal cells. Conclusions Amantadine may induce adverse reaction on comeal endothelial cells, in a dose- and duration-dependent manner.
出处 《世界临床药物》 CAS 2010年第7期417-421,共5页 World Clinical Drug
关键词 金刚烷胺 角膜内皮细胞 不良反应 amantadine corneal endothelium adverse reaction
  • 相关文献

参考文献12

  • 1Blanchard DL, Amantadine caused corneal edema [J]. Cornea, 1990, 9(2): 181.
  • 2Fraunfelder FT, Meyer SM. Amantadine and corneal deposits [J]. Am J Ophthalmol, 1990, 110 (1) : 96-97.
  • 3Nogaki H, Morimatsu M. Superficial punctate keratitis and corneal abrasion due to amantadine hydrochloride [J]. J Neurol, 1993, 240 (6) : 388-389.
  • 4Kubo S, Iwatake A, Ebihara N, et al. Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature [J]. Parkinsonism Relat Disord, 2008, 14(2): 166-169.
  • 5Chang KC, Kim MK, Wee WR, et al. Corneal endothelial dysfunction associated with amantadine toxicity [J]. Cornea, 2008, 27 (10) : 1182-1185.
  • 6Dubow JS, Rezak M, Berman AA. Reversible corneal edema associated with amantadine use: an unrecognized problem [J]. Mov Disord, 2008, 23 (14) : 2096-2097.
  • 7Jeng BH, Galor A, Lee MS, et al. Amantadine-associated corneal edema potentially irreversible even after cessation of the medication [J]. Ophthalmology, 2008, 115 (9) : 1540- 1544.
  • 8Gelb D J, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease [J]. Arch Neurol, 1999, 56 (1) : 33-39.
  • 9中国帕金森病治疗指南(第二版)[J].中华神经科杂志,2009,42(5):352-355. 被引量:171
  • 10Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality[J]. Neurology, 1967, 17 (5): 427-442.

二级参考文献25

  • 1陈生弟.帕金森病治疗指南[J].中华神经科杂志,2006,39(6):409-412. 被引量:103
  • 2温洪波,张振馨,罗毅,陈生弟,蒋雨平,张小英,孙相如,王新德,姚晨.普拉克索治疗帕金森病的多中心、随机、双盲、溴隐亭对照临床疗效和安全性研究[J].中华神经科杂志,2006,39(9):604-608. 被引量:63
  • 3Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson' s disease. N Engl J Med, 1993, 328 : 176-183.
  • 4Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson' s disease. Mov Disord, 2008, 24:562-571.
  • 5Bonuccelli U, Pavese N. Role of dopamine agonists in Parkinson' s disease : an update. Expert Rev Neurother, 2007, 7 : 1391-1399.
  • 6Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol, 2002, 59 : 1541-1550.
  • 7Albin RL, Frey KA. Initial agonist treatment of Parkinson disease : a critique. Neurology, 2003, 60 : 390-394.
  • 8Olanow W, Schapira AH, Rascol O. Continuous dopamine- receptor stimulation in early Parkinson' s disease. Trends Neurosci, 2000, 23 ( 10 Suppl) : Sl17-126.
  • 9Olanow CW, Watts RL, Koller WC. An algorithm ( decision tree) for the management of Parkinson' s disease ( 2001 ) : treatment guidelines. Neurology, 2001,56 ( 11 Suppl 5 ) : S1-S88.
  • 10Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson' s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I : early (uncomplicated) Parkinson' s disease. Eur J Neurol, 2006, 13 : 1170-1185.

共引文献170

同被引文献85

引证文献10

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部